| Identification | Back Directory | [Name]
1-butylbiguanide | [CAS]
692-13-7 | [Synonyms]
DBV
W 37
H 224
Buformin
Glybigid
Buformine
Butformin
Dibetos B
Butylbiguanide
Butyldiguanide
1-butylbiguanide
N1-Butylbiguanide
N-BUTYLBIGUANIDINE
N-Butyl-idodicarbonimidic Diamide
2-butyl-1-(diaminomethylene)guanidine
2-butyl-1-(diaminomethylidene)guanidine
Buformin (base and/or unspecified salts)
1-[bis(azanyl)methylidene]-2-butyl-guanidine | [EINECS(EC#)]
211-726-4 | [Molecular Formula]
C6H15N5 | [MDL Number]
MFCD00242653 | [MOL File]
692-13-7.mol | [Molecular Weight]
157.217 |
| Chemical Properties | Back Directory | [Melting point ]
174-176 °C | [Boiling point ]
271.89°C (rough estimate) | [density ]
1.0291 (rough estimate) | [refractive index ]
1.8070 (estimate) | [pka]
12.27±0.10(Predicted) | [InChI]
InChI=1S/C6H15N5/c1-2-3-4-10-6(9)11-5(7)8/h2-4H2,1H3,(H6,7,8,9,10,11) | [InChIKey]
XSEUMFJMFFMCIU-UHFFFAOYSA-N | [SMILES]
C(=N)(NCCCC)NC(=N)N |
| Hazard Information | Back Directory | [Uses]
Buformin, clinically used for diabetes mellitus, is known to improve resistance to insulin in patients. It suppresses the expression of glyceraldehyde 3-phosphate dehydrogenase | [Definition]
ChEBI: Buformin is a member of the class of biguanides that is biguanide substituted by a butyl group at position 1. It is an antidiabetic drug with potential antitumor effect. It has a role as a hypoglycemic agent, a geroprotector, a radiosensitizing agent, an antineoplastic agent and an antiviral agent. It is functionally related to a biguanide. | [Brand name]
Adebit;Andebit;Andelit;Andere;Biforon;Bigunal;Biquinal;Bs-5892;Bufonamin;Bulbonin;Diabrin;Dutformin;Gliporal;Insulamin;Krebon;Panformin;Silubin retard;Sindiatil;Tidemol retard;Ziavetine. | [World Health Organization (WHO)]
Buformin is an analogue of phenformin. See WHO comment for
phenformin.
(Reference: (WHODI) WHO Drug Information, 2, 4, 1977) | [in vivo]
Buformin (oral administation; 7.6?mmol/kg of chow; 7 days) exhibits significantly reduced tumor volumes and weights, and?hinders mammary morphogenesis and proliferation in MMTV-erbB-2 transgenic mice[1] | Animal Model: | Female MMTV-erbB-2 transgenic mice[1] | | Dosage: | 7.6?mmol/kg | | Administration: | Oral administation; 7 days | | Result: | Inhibited mammary syngeneic tumor growth in MMTV-erbB-2 transgenic mice. |
|
|
| Company Name: |
LGM Pharma
|
| Tel: |
1-(800)-881-8210 |
| Website: |
www.lgmpharma.com |
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
| Company Name: |
Hubei Baidu Chemical Co., Ltd
|
| Tel: |
027-027-59106051 13627137652 |
| Website: |
www.chemicalbook.com/showsupplierproductslist329110/0_en.htm |
| Company Name: |
InvivoChem
|
| Tel: |
13549236410 |
| Website: |
https://www.invivochem.cn/ |
|